Abstract: Described herein are methods for providing a tumour-specific T cell preparation of use for treating cancer. The method encompasses, determining which T cell receptors are most likely to be reactive to a cancer in a patient, then preparing a T cell population expressing these specific T cell receptor genes from expression constructs transferred into a preparation of T cells, and administering these engineered T cells into the patient.

Abstract: The present invention relates to a method for preparing tumour-specific T cells, comprising the steps of: providing a tumour sample obtained from a patient, wherein the tumour sample comprises T cells that infiltrated the tumour; isolating T regulatory cells from the tumour sample, selecting at least one clonotype of the isolated T regulatory cells, determining the T cells receptor sequence of the selected clonotype, providing T cells other than T regulatory cells of patient, and transducing T cells other than T regulatory cells obtain from said patient with the determined TCR sequence of selected clonotype thereby yielding tumour specific T cells.

Abstract: The present invention relates to a method for providing a tumour specific T cell preparation, comprising the steps of: a. selecting tumour-specific T cell clones by: —providing a tumour sample obtained from a patient; —isolating a nucleic acid preparation from the tumour sample in a nucleic acid isolation step; —obtaining a plurality of T cell receptor nucleic acid sequences from the nucleic acid preparation or a plurality of T cell receptor amino acid sequences encoded by the plurality of T cell receptor nucleic acid sequences; —selecting a tumour-specific T cell receptor nucleic acid sequence from the plurality of T cell receptor nucleic acid sequences or a tumour-specific T cell receptor amino acid sequence from the plurality of T cell receptor amino acid sequences in a sequence selection step; b.

Abstract: Contacting apparatus for contacting an energy storage cell (1) comprising at least one printed circuit board (5) which is provided for discharging the electrical energy stored in the energy storage cell (1), wherein at least one electric pole of the energy storage cell (1) is pressed by a releasable mechanical connection (7) with a specific contact pressing force against an electrically conductive layer (5c) of the at least one printed circuit board (5) which is located on a front side of the at least one printed circuit board (5) facing the energy storage cell (1).

Abstract: Contacting apparatus for contacting an energy storage cell (1) comprising at least one printed circuit board (5) which is provided for discharging the electrical energy stored in the energy storage cell (1), wherein at least one electric pole of the energy storage cell (1) is pressed by a releasable mechanical connection (7) with a specific contact pressing force against an electrically conductive layer (5c) of the at least one printed circuit board (5) which is located on a front side of the at least one printed circuit board (5) facing the energy storage cell (1).

Abstract: The invention relates to the use of pramipexol as a pharmaceutical composition having an antidepressant activity.

Abstract: 5,11-Dihydro-6H-pyrido[2,3-b][1,4]-benzo-diazepinones substituted in the 11-position corresponding to general formula I ##STR1## wherein R.sup.1 and R.sup.2 represent hydrogen atoms or alkyl groups having 1 to 3 carbon atoms, A.sup.1 is a straight-chained or branched alkylene group with 1 to 5 carbon atoms, A.sup.2 is a methylene group or, if R.sup.1 is hydrogen and R.sup.2 is methyl, A.sup.2 may also be an ethylene group, and the physiologically acceptable acid addition salts thereof are suitable for treating bradycardia and bradyarrhythmia and spasm in the colon, bladder and bronchi.

Abstract: Compounds of general formula I are described, ##STR1## wherein X represents the group .dbd.CHR, .dbd.NR or an oxygen atom andA represents the groups --NR.sup.1 R.sup.2,wherein R.sup.1 and R.sup.2 represent alkyl, cycloalkyl or phenylalkyl groups, n represents the number 0, 1 or 2, R.sup.3 represents a hydrogen atom, a hydroxy or alkyl group or a group --(CH.sub.2).sub.n --N--R.sup.5 R.sup.6 (R.sup.5 and R.sup.6 being lower alkyl groups) and R.sup.4 is an alkyl or phenylalkyl group; two processes for preparing these compounds and the salts thereof are also described.The compounds have favourable effects on heart rate and can be used as vagal pacemakers for treating bradycardia and bradyarrhythmia in human and veterinary medicine. Some of these compounds also have very good antithrombotic effects.

Abstract: The invention relates to a process for producing steel of low phosphorus content from hot metal of usual phosphorus content, in which the hot metal is simultaneously decarburized and dephosphorized in a single process step in a metallurgical vessel, in particular in a converter. The refining gas consisting predominantly or completely of technically pure oxygen is top-blown into the melt, particularly from below. The vessel is charged with hot metal containing manganese in an amount of less than 0.2% by weight. Lime is then added and refining is carried out down to a final phosphorus content of 0.005% by weight or less in the steel at the end of blowing, without a change of slag.

Abstract: The invention relates to a process for desulphurizing hot metal in a ladle, in particular in a torpedo ladle, wherein first aluminum and then, by means of a carrier gas, lime (CaO) are blown into the hot metal. The characterizing feature of the invention is that at a rate of 2-20 liters (S.T.P.) of carrier gas/kg of desulphurizing agent, a solid which evolves a gas in the hot metal is blown in together with the lime.

Abstract: The invention relates to novel substituted 5,11-dihydro-6H-dibenz[b,e]azepin-6-one of the formula ##STR1## wherein A represents a (1-methyl-4-piperidinyl)-acetyl, (4-methyl-1-piperazinyl)-acetyl, or [(1-methyl-4-piperidinyl)-amino]-carbonyl group,and the acid addition salts thereof, which have valuable pharmacological properties, particularly an ulcer-inhibiting and secretion-inhibiting activity. The compounds of Formula I may be prepared using methods conventionally used for analogous compounds.

Abstract: Disclosed are novel condensed diazepinones of formula I ##STR1## wherein B is a fused ring selected from ##STR2## X is --CH-- or, when B is ortho-phenylene, X can also be nitrogen; A.sub.1 is C.sub.1 -C.sub.2 alkylene; A.sub.2 is C.sub.1 -C.sub.2 when it is in the 2-position relative to the saturated heterocyclic ring nitrogen or a single bond or methylene when it is in the 3- or 4-position; R.sub.1 is C.sub.1 -C.sub.3 alkyl; R.sub.2 is C.sub.1 -C.sub.7 alkyl, optionally hydroxy-substituted on at least one of its second to seventh carbon, or C.sub.3 -C.sub.7 cycloalkyl, optionally hydroxy substituted, or C.sub.3 -C.sub.7 cycloalkylmethyl; or R.sub.1 and R.sub.2 can, together with the nitrogen therebetween, be a 4- to 7-membered saturated monocyclic, heterocyclic ring which can optionally include an oxygen or N--CH.sub.3 ; R.sub.3 is hydrogen, chlorine, or methyl; R.sub.4 is hydrogen or C.sub.1 -C.sub.4 alkyl, R.sub.5 is hydrogen, chlorine or C.sub.1 -C.sub.

Abstract: The specification describes new substituted dibenzodiazepinones of formula ##STR1## wherein R.sub.1 is hydrogen or chlorine atom and R is (1-methyl-4-piperidinyl)methyl, (1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)methyl,1-methyl-1,2,5,6-tetrahydr o-4-pyridinyl, (1-methyl-4-piperidinylidene)methyl,(2,3-dehydro-8-methyl-8-aza-bicyclo[3, 2,1]oct-3-yl)-methyl, (8-methyl-8-aza-bicyclo[3,2,1]oct-3-ylidene)-methyl or an endo-or exo-(8-methyl-8-azabicyclo[3,2,1]oct-3-yl)methyl each being optionally substituted by one or two methyls on the heterocyclic ring, and the nontoxic, pharmaceutically acceptable acid addition salts thereof, processes for preparing them and pharmaceutical compositions containing these compounds.The compounds of formula I have an antiulcerative effect and an inhibitory effect on the secretion of gastric substances having anticholinergic activity, such as dryness of the mouth and mydriasis.

Abstract: This invention relates to compounds of the formula ##STR1## wherein X is oxygen, --NH--, or--NCH.sub.3 --andR is 1-methyl-4-piperidinyl, 4-methyl-1-piperazinyl, endo-8-methyl-8-azabicyclo[3.2.1]oct-3-yl, or exo-8-methyl-8-acabicyclo[3.2.1]oct-3-yl, each of which may optionally have an additional methyl substitutent,a diastereomer or enantiomer thereof, or a non-toxic, pharmacologically acceptable acid addition salt thereof with an inorganic or organic acid.

Abstract: A process is described and claimed for reducing the iron content of a CaO-rich slag which is formed during the desulphurization of molten crude iron which comprises adding finely-ground fluorspar to the melt, in the ladle, or adding it to the lade prior to adding the crude iron thereto, in an amount such that the slag is not rendered fluid.

Abstract: This invention relates to novel compounds of the formula ##STR1## wherein R.sub.1 is hydrogen or alkyl having from 1 to 4 carbon atoms;R.sub.2 is halogen, hydrogen, or alkyl having from 1 to 4 carbon atoms; andR is (1-methyl-4-piperidinyl)methyl, (1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)methyl, 1-methyl-1,2,5,6-tetrahydro-4-pyridinyl, (1-methyl-4-piperidinylidene)-methyl, or (8-methyl-8-azabicyclo?3.2.1!oct-3-yl)-methyl, each of which can optionally have an additional methyl substituent on the heterocyclic ring,and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as anti-ulcerogenics.

Abstract: New pyridobenzodiazepinones of the formula ##STR1## are described wherein X represents oxygen, --NH-- or --NCH.sub.3 -- and R represents 1-methyl-4-piperidinyl or 4-methyl-1-piperazinyl group optionally substituted by a methyl group, or a 3.alpha.- or 3.beta.-tropanyl group, and the nontoxic pharmaceutically acceptable acid addition salts thereof. The specification also describes processes for preparing these compounds, pharmaceutical compositions containing these compounds and new intermediate products used in preparing them.The compounds of formula I have antiulcerative effects and an inhibitory effect on gastric acid secretion, without the side effects such as dryness of the mouth and mydriasis which occur with other substances having an anticholinergic activity.

Abstract: This invention relates to compounds of the formula ##STR1## wherein R is (1-methyl-4-piperidinyl)methyl, (1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)methyl, 1-methyl-1,2,5,6-tetrahydro-4-pyridinyl, (1-methyl-4-piperidinylidene)methyl, 2,3-dehydro-8-methyl-8-azabicyclo?3.2.1!oct-3-yl methyl, endo-8-methyl-8-azabicyclo?3.2.1!oct-3-yl-methyl, or exo-8-methyl-8-azabicyclo?3.2.1!oct-3-yl-methyl, each of which may optionally have one or two methyl substituents on the six-membered heterocyclic ring, and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as anti-ulcerogenics.

Abstract: Compounds of the formula ##STR1## wherein R is 1-methyl-4-piperididinyl, 4-methyl-1-piperazinyl, or 3 - or 3 -tropanyl, each of which may optionally have another methyl substituent attached to the heterocyclic ring;R.sub.1 is hydrogen or alkyl of 1 to 4 carbon atoms;R.sub.2 is hydrogen, halogen or alkyl of 1 to 4 carbon atoms; andX is oxygen, --NH-- or --N(CH.sub.3)--;and non-toxic, pharmacologically acceptable acid addition salts thereof. The compounds as well as their salts are useful as anti-ulcerogenics.